September 26th, 2025 | 07:30 CEST
AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry
Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.
time to read: 3 minutes
|
Author:
Nico Popp
ISIN:
SAP SE O.N. | DE0007164600 , AMAZON.COM INC. DL-_01 | US0231351067 , NETRAMARK HOLDINGS INC | CA64119M1059
Table of contents:
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
NetraMark: Clinical research even with small data sets
After SAP announced its AI collaboration with OpenAI and Amazon, its share price jumped significantly. Observers see the partnership as the next logical step. It is now clear that Europe aims to develop its own AI infrastructure. Amazon is building data centers in Brandenburg for this purpose through its AWS cloud service. In the future, the two companies also aim to advance the digitization of German companies and support them in developing AI applications based on their own data. This step makes perfect sense: SAP systems already store vast amounts of data, often with long historical records. So far, however, relatively few small and mid-sized companies have considered leveraging this treasure trove of data for their own benefit.
When one hears how professional thinkers such as philosopher Markus Gabriel assess the possibilities of AI, it quickly becomes clear that there is enormous potential here. The Canadian company NetraMark has been harnessing this potential for several years and applying the possibilities of AI in medical research. The Company's proprietary NetraAI platform is based on a novel "topology-based" algorithm that segments patient records into homogeneous subgroups. This enables NetraMark to work with even small data sets, differentiate diseases into precise subtypes, and classify patients based on drug sensitivity. This expertise helps to set up drug studies in such a way that maximizes the likelihood of success.
Collaborations on glioblastoma and pediatric heart disease
NetraAI enables researchers to plan drug studies in a more targeted manner, for example, by selecting appropriate inclusion criteria and biomarkers. Just a few days ago, NetraMark announced a collaboration with a leading US research center on glioblastoma, a particularly aggressive brain tumor. Through this partnership, the Canadians will gain access to extensive data, which NetraAI will analyze and derive explainable patient subgroups from it. According to NetraMark President Josh Spiegel, these subgroups will facilitate the discovery of new biomarkers. In the summer of 2025, NetraMark entered into a collaboration with Asklepion Pharmaceuticals. The biotech company is using NetraMark technology in a Phase III study for pediatric heart disease. This technology is particularly valuable for studies with a limited number of participants.
Also in the summer, NetraMark announced a collaboration with data analysis specialist Pentara. The goal: to detect anomalies in clinical trials using AI – undetected data integrity issues can distort efficacy signals and compromise the validity of study conclusions. The earlier researchers detect these anomalies, the better. After months without announcing any major collaborations, the three company announcements show that NetraMark's technology is compatible with many areas. The tech company was already working with the contract research organization Worldwide Clinical Trials – it seems that NetraMark is convincing more and more industry representatives.
Versatile connectivity – What is next for NetraMark shares?
Considering that the development of a new active ingredient typically takes many years – industry representatives cite 10–15 years – and costs hundreds of millions to several billion USD, it becomes clear how much leverage NetraMark offers to biotech companies. The stock has recently seen a jump, but over the past six months, it has only posted a return of around 20%. The market capitalization of just around EUR 80 million does not yet indicate any exaggeration. NetraMark is an AI stock with interesting prospects. If it succeeds in concluding its existing partnerships, the Company is likely to generate follow-up orders or even attract the attention of major pharmaceutical companies or contract research organizations. AI is a technology poised to transform many sectors of the economy, and its advantages in biotechnology are obvious. NetraMark has already successfully occupied this niche. Given these fundamentals, the stock has significant potential, and the market does not yet appear to have fully priced it in.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
